SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVictrex Regulatory News (VCT)

Share Price Information for Victrex (VCT)

Share Price is delayed by 15 minutes
Get Live Data
620.00    9.00 (1.47%)
Bid:
621.00
Ask:
623.00
Spread: 2.00 (0.322%)
Market Cap: £540.17m
VCT Live PriceLast checked at - London Stock Exchange

Intraday Victrex Share Chart

Trading Statement

8 Oct 2015 07:00

RNS Number : 5861B
Victrex PLC
08 October 2015
 



 

 

 

 

 

 

8 October 2015

 

Victrex plc - Full year pre-close trading update

 

"A good finish to 2015"

 

Victrex plc, an innovative world leader in high performance polymer solutions, today announces its full year pre-close trading update for the financial year ended 30 September 2015, ahead of its preliminary results on 8 December 2015.

 

Victrex delivered a good finish to 2015, with overall performance in line with our expectations, including a robust fourth quarter (Q4). For the year as a whole, the value of our balanced portfolio helped to drive growth and fully overcome headwinds including weaker sales in Oil & Gas, the effects of US Spine market consolidation on our Invibio medical business and the significant impact from foreign currency this year.

 

On a reported basis, full year Group revenue of £263.5m was 4% ahead of the prior year (FY 2014: £252.6m), with Q4 Group revenue of £68.7m being flat on the prior year period. Foreign currency, at a profit level, was a headwind of approximately £8m for the full year, which we will fully overcome.

 

At a volume level, full year Group sales volume of 4,217 tonnes was 19% ahead of the prior year (FY 2014: 3,551 tonnes). Q4 Group sales volume of 1,119 tonnes was 6% ahead of the prior year period (Q4 2014: 1,056 tonnes). Sales volumes reflect our overall momentum in VPS remaining positive during the fourth quarter, with growth across Aerospace, Automotive, General Industrial and strong Consumer Electronics volumes offsetting Oil & Gas, as previously communicated.

 

Invibio performance was in line with our previous guidance, with full year revenue of £50.5m being 5% down compared to the prior year (FY 2014: £53.4m). This reflects the effects of consolidation in the US Spine market.

 

Outlook

Our overall growth momentum remains positive as we start our new financial year. Whilst we are mindful of the continuing weakness in Oil & Gas and the need to improve Invibio performance in 2016, our balanced portfolio keeps us well placed to continue driving growth and creating value, in line with our long term strategy.

 

Enquiries:

 

Victrex plc:

Andrew Hanson, Head of Investor Relations & Communications +44 (0) 1253 898121

Louisa Burdett, Group Finance Director +44 (0) 1253 897700

David Hummel, Chief Executive +44 (0) 1253 897700

 

Pendomer Communications:

Charles Armitstead +44 (0) 203 603 5220

 

About Victrex:

Victrex is an innovative world leader in high performance polymer solutions focused on the Aerospace, Automotive, Electronics, Energy and Medical markets. Every day, millions of people rely on products or applications which contain our polymers, from smartphones, aeroplanes and cars to oil & gas operations and medical devices. With over 35 years' experience, we are delivering leading edge solutions to shape future performance for our customers and our markets, and to drive value for our shareholders. Find out more at www.victrexplc.com

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTUGGQWUUPAGAM
Date   Source Headline
29th May 202611:00 amRNSTotal Voting Rights
18th May 20268:50 amRNSDirectorate change
11th May 20267:00 amRNSHalf-year Financial Report
30th Apr 202610:46 amRNSTotal Voting Rights
29th Apr 20264:28 pmRNSHolding(s) in Company
31st Mar 20261:37 pmRNSTotal Voting Rights
24th Mar 20264:29 pmRNSHolding(s) in Company
24th Mar 20262:03 pmRNSHolding(s) in Company
20th Mar 20269:38 amRNSHolding(s) in Company
27th Feb 20262:40 pmRNSTotal Voting Rights
27th Feb 20261:02 pmRNSHolding(s) in Company
24th Feb 202611:41 amRNSHolding(s) in Company
17th Feb 20263:06 pmRNSDirector/PDMR Shareholding
12th Feb 20263:26 pmRNSDirector/PDMR Shareholding
12th Feb 20263:22 pmRNSDirector/PDMR Shareholding
10th Feb 20262:43 pmRNSDirector/PDMR Shareholding
10th Feb 20269:00 amRNSDirectorate change
6th Feb 20261:33 pmRNSResult of AGM
6th Feb 20267:00 amRNSQ1 Trading Update
30th Jan 202611:49 amRNSTotal Voting Rights
28th Jan 202612:25 pmRNSHolding(s) in Company
22nd Jan 202610:21 amRNSHolding(s) in Company
20th Jan 20261:26 pmRNSAdditional Listing
31st Dec 20259:00 amRNSTotal Voting Rights
31st Dec 20259:00 amRNSTotal Voting Rights
22nd Dec 202512:00 pmRNSAnnual Financial Report
22nd Dec 202512:00 pmRNSAnnual Financial Report
18th Dec 202511:49 amRNSDirector/PDMR Shareholding - Replacement
17th Dec 20253:42 pmRNSDirector/PDMR Shareholding
17th Dec 202512:08 pmRNSDirector/PDMR Shareholding
15th Dec 20259:00 amRNSDirector/PDMR Shareholding
11th Dec 20258:52 amRNSDirector/PDMR Shareholding
5th Dec 20259:30 amRNSShare purchase by incoming Director (incoming CEO)
4th Dec 20259:06 amRNSFinancial Calendar Update
2nd Dec 20257:00 amRNSPreliminary Results
1st Dec 202510:49 amRNSBlock listing Interim Review
28th Nov 20259:27 amRNSTotal Voting Rights
20th Nov 20259:05 amRNSAdditional Listing
7th Nov 202510:39 amRNSHolding(s) in Company
31st Oct 20258:58 amRNSTotal Voting Rights
21st Oct 20257:30 amRNSCEO Succession update
3rd Oct 202511:36 amRNSHolding(s) in Company
3rd Oct 20259:03 amRNSHolding(s) in Company
30th Sep 20259:54 amRNSTotal Voting Rights
29th Aug 202510:16 amRNSTotal Voting Rights
31st Jul 20259:14 amRNSTotal Voting Rights
9th Jul 20251:02 pmRNSHolding(s) in Company
8th Jul 20253:33 pmRNSDirector/PDMR Shareholding
8th Jul 20257:00 amRNSDirectorate change: CEO succession
8th Jul 20257:00 amRNSQ3 Trading Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.